PL2151439T3 - Pochodna z wprowadzonym atomem azotu i 6-członowym pierścieniem aromatycznym oraz zawierający ją środek farmaceutyczny - Google Patents

Pochodna z wprowadzonym atomem azotu i 6-członowym pierścieniem aromatycznym oraz zawierający ją środek farmaceutyczny

Info

Publication number
PL2151439T3
PL2151439T3 PL08764246T PL08764246T PL2151439T3 PL 2151439 T3 PL2151439 T3 PL 2151439T3 PL 08764246 T PL08764246 T PL 08764246T PL 08764246 T PL08764246 T PL 08764246T PL 2151439 T3 PL2151439 T3 PL 2151439T3
Authority
PL
Poland
Prior art keywords
same
membered ring
pharmaceutical agent
ring derivative
nitrogenated aromatic
Prior art date
Application number
PL08764246T
Other languages
English (en)
Inventor
Naohiro Takemoto
Kenji Murata
Norihito Murayama
Chikaomi Yamada
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of PL2151439T3 publication Critical patent/PL2151439T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08764246T 2007-04-27 2008-04-25 Pochodna z wprowadzonym atomem azotu i 6-członowym pierścieniem aromatycznym oraz zawierający ją środek farmaceutyczny PL2151439T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007118768 2007-04-27
EP20080764246 EP2151439B1 (en) 2007-04-27 2008-04-25 Nitrogenated aromatic 6-membered ring derivative, and pharmaceutical agent comprising the same
PCT/JP2008/058081 WO2008139894A1 (ja) 2007-04-27 2008-04-25 含窒素芳香族６員環誘導体並びにそれらを含む医薬

Publications (1)

Publication Number Publication Date
PL2151439T3 true PL2151439T3 (pl) 2014-08-29

Family

ID=40002110

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08764246T PL2151439T3 (pl) 2007-04-27 2008-04-25 Pochodna z wprowadzonym atomem azotu i 6-członowym pierścieniem aromatycznym oraz zawierający ją środek farmaceutyczny

Country Status (18)

Country Link
US (4) US8592435B2 (pl)
EP (2) EP2679586B1 (pl)
JP (1) JP5197584B2 (pl)
KR (1) KR101456316B1 (pl)
CN (2) CN101730691A (pl)
AU (1) AU2008249329C1 (pl)
BR (1) BRPI0810821A8 (pl)
CA (1) CA2683941C (pl)
CY (1) CY1115377T1 (pl)
DK (1) DK2151439T3 (pl)
ES (2) ES2566327T3 (pl)
HR (1) HRP20140326T1 (pl)
MX (1) MX2009011369A (pl)
PL (1) PL2151439T3 (pl)
PT (1) PT2151439E (pl)
RU (1) RU2470927C2 (pl)
SI (1) SI2151439T1 (pl)
WO (1) WO2008139894A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112284C2 (uk) * 2009-08-07 2016-08-25 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Похідні 5-фторпіримідинону
ES2506169T3 (es) * 2009-08-07 2014-10-13 Dow Agrosciences Llc Derivados de 5-fluoro-2-oxopirimidina-1(2H)-carboxilato como fungicidas
MX2015008444A (es) 2012-12-28 2015-09-23 Dow Agrosciences Llc Derivados de n-(sustituido)-5-flouro-4-imino-3-metil-2-oxo-3,4-dih idropirimidin-1 (2h)-carboximida.
AU2013370493B2 (en) 2012-12-28 2017-08-17 Adama Makhteshim Ltd. N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1 (2H)-carboxylate derivatives
KR102309245B1 (ko) 2012-12-31 2021-10-06 아다마 마켓심 리미티드 살진균제로서의 3-알킬-5-플루오로-4-치환된-이미노-3,4-디히드로피리미딘-2(1h)-온 유도체
WO2016047662A1 (ja) * 2014-09-25 2016-03-31 第一三共株式会社 脳卒中の治療剤
WO2016086105A1 (en) * 2014-11-25 2016-06-02 Shriners Hospitals For Children MODEL SYSTEMS FOR SCREENING MODULATORS OF mTOR SIGNALING
CN114570418B (zh) * 2022-02-22 2023-10-17 陕西延长石油（集团）有限责任公司 一种羟基乙酸甲酯制备肌氨酸甲酯及肌氨酸的催化剂及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1260474A (en) * 1984-12-03 1989-09-26 Raymond A. Stokbroekx Benzoxazol- and benzothiazolamine derivatives
GB8912700D0 (en) * 1989-06-02 1989-07-19 Shell Int Research Herbicidal compounds
DE68914197T2 (de) 1988-06-20 1994-11-10 Ihara Chemical Ind Co Alkansäurederivate und herbizide Mittel.
JP2771604B2 (ja) * 1988-06-20 1998-07-02 クミアイ化学工業株式会社 除草剤及びその有効成分となる新規なアルカン酸誘導体
GB8917476D0 (en) * 1989-07-31 1989-09-13 Shell Int Research Sulphonamide herbicides
AU762345B2 (en) * 1998-10-16 2003-06-26 Asubio Pharma Co., Ltd. Aminophenoxyacetic acid derivatives as neuroprotectants
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
KR100853968B1 (ko) 2000-04-13 2008-08-25 아스비오파마 가부시키가이샤 아미노페녹시아세트아미드 유도체 및 그를 함유하는약제학적 조성물
US7115635B2 (en) 2001-04-27 2006-10-03 Mitsubishi Pharma Corporation Benzylpiperidine compound
US7205307B2 (en) 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
KR20050008846A (ko) 2002-06-24 2005-01-21 아카디아 파마슈티칼스 인코포레이티드 세로토닌 수용체 제제로서의 ｎ-치환된 피페리딘 유도체
JP4916115B2 (ja) 2004-01-29 2012-04-11 大塚製薬株式会社 血管新生促進剤
MY142362A (en) 2004-01-29 2010-11-30 Otsuka Pharma Co Ltd Pharmaceutical composition for promoting angiogenesis
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
US20090197914A1 (en) 2006-03-07 2009-08-06 Peter Cage Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them

Also Published As

Publication number Publication date
AU2008249329C1 (en) 2013-07-04
EP2151439A1 (en) 2010-02-10
MX2009011369A (es) 2009-12-15
HRP20140326T1 (hr) 2014-05-09
AU2008249329A1 (en) 2008-11-20
EP2679586B1 (en) 2016-02-10
SI2151439T1 (sl) 2014-05-30
US9156817B2 (en) 2015-10-13
WO2008139894A1 (ja) 2008-11-20
KR101456316B1 (ko) 2014-11-03
CN103396399A (zh) 2013-11-20
US20140221409A1 (en) 2014-08-07
BRPI0810821A2 (pt) 2014-10-29
JPWO2008139894A1 (ja) 2010-07-29
BRPI0810821A8 (pt) 2015-09-15
US20140336209A1 (en) 2014-11-13
CN103396399B (zh) 2015-04-29
CY1115377T1 (el) 2017-01-04
RU2009143850A (ru) 2011-06-10
CA2683941C (en) 2014-08-12
AU2008249329B2 (en) 2012-12-06
EP2151439B1 (en) 2014-02-26
EP2679586A1 (en) 2014-01-01
US8685989B2 (en) 2014-04-01
JP5197584B2 (ja) 2013-05-15
DK2151439T3 (en) 2014-03-10
CA2683941A1 (en) 2008-11-20
EP2151439A4 (en) 2012-08-01
US9139559B2 (en) 2015-09-22
PT2151439E (pt) 2014-04-10
KR20100017388A (ko) 2010-02-16
US20100130739A1 (en) 2010-05-27
RU2470927C2 (ru) 2012-12-27
ES2453590T3 (es) 2014-04-08
CN101730691A (zh) 2010-06-09
ES2566327T3 (es) 2016-04-12
US8592435B2 (en) 2013-11-26
US20120258978A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP2157093A4 (en) HETEROCYCLIC PYRROLO-NITROGEN-DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL USE
IL188050A (en) The history of azaindazole, their medicinal preparations and their uses
IL206395A (en) N- Heterocyclic-7-Oxo-6-Sulphoxy-6,1-Diazabicyclo [1.2.3] Octane-2-Carboxamides and Pharmaceuticals Containing Them
IL193240A0 (en) Dihydrodiazepine derivatives and pharmaceutical compositions containing the same
IL198509A0 (en) Azaindole derivatives, compositions containing the same and uses thereof
IL225206A (en) A derivative of multinuclear carbamoylpyridone, its pharmaceutical composition and its use
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
IL203915A (en) Annotations of 2-Benzylphenyl-6-Hydroxymethyl-Tetrahydro-2 H-Pyrene-3,4,5-Triol
ZA200709856B (en) Fluorene derivatives,compositions containing said derivatives and the use thereof
IL198289A (en) Processed dihydropyrazolones, processes for their preparation, medicinal preparations containing them and their use in the preparation of medicinal preparations
IL191902A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL202376A (en) History of pyridazinone, drugs and their kit containing and use
EP2143724A4 (en) NUCLEOUS FUSED CYBLE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF FOR MEDICAL USES
BRPI0813455A2 (pt) Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado.
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
IL187235A0 (en) 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
SI2151439T1 (sl) Nitrogeniran aromatski derivat s 6-členskim obročem in farmacevtsko sredstvo, ki obsega ta derivat
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
ZA201009097B (en) C-ring-substituted pregn-4-ene-21,17-carbolactone,and pharmaceutical preparations comprising the latter
IL208168A0 (en) Tetrahydroisoquinoline derivatives, compositions comprising the same and use thereof
SI2266619T1 (sl) Farmacevtski sestavek na osnovi hepatoprotektorja in prebiotika, njegova izdelava in uporaba